The purpose of this study is to evaluate drug-drug interaction by comparing the pharmacokinetics (PK)/pharmacodynamics (PD), safety, and tolerability of single/multiple doses of DWP16001 , DWC202204 and DWC202205 alone or in combination in healthy male adults.
\* Open label, multiple dose, 2 part, two period, single sequence design. This study is conducted on open label because it evaluates PK/PD parameters that are not affected by the blind. Volunteers who are suitable for the inclusion criteria are granted the final target number before the first dosage, receiving a fixed IP, and conducting a planned clinical trial schedule. After having a rest period (7 days) in which the drug received is sufficiently metabolized and lost, the IP of the next period is administered.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
53
Tablets, Oral, multiple doses of DWP16001
Tablets, Oral, multiple doses of DWC202204 and DWC202205 in combination
Tablets, Oral, DWP16001 , multiple doses of DWC202204 and DWC202205 in combination
Cmax,ss of DWP16001
Peak Plasma Concetration at steady-state
Time frame: [Time Frame: 0-72 hours]
AUCtau,ss of DWP16001
Area under the plasma concentration versus time curve at Tau, steady-state
Time frame: [Time Frame: 0-72 hours]
Cmax,ss of DWC202204 and DWC202205
Peak Plasma Concetration at steady-state
Time frame: [Time Frame: 0-24 hours]
AUCtau,ss of DWC202204 and DWC202205
Area under the plasma concentration versus time curve at Tau, steady-state
Time frame: [Time Frame: 0-24 hours]
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.